FDA approves Exjade to treat excess iron in patients with non-transfusion-dependent thalassemia

Author(s):

On Jan. 23, 2013, the U.S. Food and Drug Administration (FDA) approved the use of Exjade (deferasirox) to treat patients ages 10 years and older who have chronic iron overload resulting from non-transfusion-dependent thalassemia, a milder form of thalassemia. Read more.

LEAVE A REPLY

Please enter your comment!
Please enter your name here